



**Ongoing Disclosure Notice**

**Disclosure of Directors and Senior Managers Relevant Interests**

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

For personal use only

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
16 September 2025
5 September 2025

**Director or senior manager giving disclosure**

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Andrew Robert Donald Somervell
Fisher & Paykel Healthcare Corporation Limited
Vice President - Products & Technology

**Summary of acquisition or disposal of relevant interest (excluding specified derivatives)**

Class of affected quoted financial products:
Nature of the affected relevant interest(s):

a) Options to acquire Ordinary Shares
b) Performance Share Rights
c) Ordinary Shares
Beneficial Interest

**For that relevant interest-**

Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

a) 124,441 Options to acquire Ordinary Shares
b) 63,810 Performance Share Rights
c) 110,351 Ordinary Shares
a) 85,423 Options to acquire Ordinary Shares
b) 46,615 Performance Share Rights
c) 146,624 Ordinary Shares
Andrew Robert Donald Somervell
Andrew Robert Donald Somervell

**Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)**

Type of affected derivative:
Class of underlying financial products:


**Details of affected derivative-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:


*For that derivative,-*

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:


**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:
---

Two
-----

**Details of transactions requiring disclosure-**

Date of transaction:
Nature of transaction:
Name of any other party or parties to the transaction (if known):

a) 10 September 2025
b) 10 September 2025
a) Exercise and cancellation of Options and Issue of Ordinary Shares
b) Exercise of Performance Share Rights and Issue of Ordinary Shares

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

--

Number of financial products to which the transaction related:

*If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—*

Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:
Date of the prior written clearance (if any):

a) Exercise price of \$19.63 per Ordinary Share  
b) Nil

a) Exercise of 39,018 Options and Issue of 19,078 Ordinary Shares  
b) Exercise 17,195 Performance Share Rights and Issue of 17,195 Ordinary Shares


**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:
Nature of relevant interest:
<i>For that relevant interest,-</i>
Number held in class:
Current registered holder(s):
<i>For a derivative relevant interest,-</i>
Type of derivative:


**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
<i>For that derivative relevant interest,-</i>
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:


**Certification**

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:
Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:


*Raelene Leonard*  
16 September 2025  
Raelene Leonard,  
General Counsel & Company Secretary



**Ongoing Disclosure Notice**  
**Disclosure of Directors and Senior Managers Relevant Interests**  
*Sections 297(2) and 298(2), Financial Markets Conduct Act 2013*

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
16 September 2025
5 September 2025

**Director or senior manager giving disclosure**

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Andrew Grant Niccol
Fisher & Paykel Healthcare Corporation Limited
Chief Operating Officer

**Summary of acquisition or disposal of relevant interest (excluding specified derivatives)**

Class of affected quoted financial products:
Nature of the affected relevant interest(s):

a) Options to acquire Ordinary Shares
b) Performance Share Rights
c) Ordinary Shares
Beneficial Interest

**For that relevant interest-**

Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

a) 31,142 Options to acquire Ordinary Shares
b) 21,690 Performance Share Rights
c) 3,559 Ordinary Shares
a) 23,056 Options to acquire Ordinary Shares
b) 18,126 Performance Share Rights
c) 7,376 Ordinary Shares
Andrew Grant Niccol
Andrew Grant Niccol

**Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)**

Type of affected derivative:
Class of underlying financial products:


**Details of affected derivative-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:


**For that derivative,-**

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:


**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:
---

Three
-------

**Details of transactions requiring disclosure-**

Date of transaction:
Nature of transaction:
Name of any other party or parties to the transaction (if known):

a) 11 September 2025
b) 10 September 2025
c) 12 September 2025
a) Exercise and cancellation of Options and Issue of Ordinary Shares
b) Exercise of Performance Share Rights and Issue of Ordinary Shares
c) Sale of Ordinary Shares

For personal use only

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

--

Number of financial products to which the transaction related:  
 If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:
Date of the prior written clearance (if any):

**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:
Nature of relevant interest:
<i>For that relevant interest,-</i>
Number held in class:
Current registered holder(s):
<i>For a derivative relevant interest,-</i>
Type of derivative:

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
<i>For that derivative relevant interest,-</i>
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

**Certification**

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:
Date of signature:


or

Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

a) Exercise price of \$19.63 per Ordinary Share
b) Nil
c) \$38.0978 per Ordinary Share
a) Exercise of 8,086 Options and Issue of 3,953 Ordinary Shares
b) Exercise of 3,564 Performance Share Rights and Issue 3,564 Ordinary Shares
c) Sale of 3,700 Ordinary Shares






16 September 2025
Raelene Leonard, General Counsel & Company Secretary



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
16 September 2025
5 September 2025

#### Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Lewis George Gradon
Fisher & Paykel Healthcare Corporation Limited
Chief Executive Officer

#### Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):

a) Options to acquire Ordinary Shares
b) Performance Share Rights
c) Ordinary Shares
Beneficial interest

#### For that relevant interest-

Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

a) 401,061 Options to acquire Ordinary Shares
b) 201,762 Performance Share Rights
c) 574,224 Ordinary Shares
a) 272,290 Options to acquire Ordinary Shares
b) 145,013 Performance Share Rights
c) 558,934 Ordinary Shares
a) Lewis George Gradon
b) Lewis George Gradon
c) Lewis George Gradon; Gradon Family Trust
a) Lewis George Gradon
b) Lewis George Gradon
c) Lewis George Gradon; Gradon Family Trust

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:


#### Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:


#### For that derivative,-

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:


#### Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:
---

Four
------

For personal use only

For personal use only

**Details of transactions requiring disclosure-**

Date of transaction:	a) 11 September 2025 b) 10 September 2025 c) 12 September 2025 d) 15 September 2025
Nature of transaction:	a) Exercise and cancellation of Options and Issue of Ordinary Shares b) Exercise of Performance Share Rights and Issue of Ordinary Shares c) Sale of Ordinary Shares d) Sale of Ordinary Shares
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:	a) Exercise price of \$19.63 per Ordinary Share b) Nil c) \$38.0623 per Ordinary Share d) \$37.6116 per Ordinary Share
Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	a) Exercise of 128,771 Options and Issue of 62,961 Ordinary Shares b) Exercise of 56,749 Performance Share Rights and Issue of 56,749 Ordinary Shares c) Sale of 79,445 Ordinary Shares d) Sale of 55,555 Ordinary Shares
Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	


**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:	
Nature of relevant interest:	
<i>For that relevant interest,-</i>	
Number held in class:	
Current registered holder(s):	
<i>For a derivative relevant interest,-</i>	
Type of derivative:	

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative relevant interest,-</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

**Certification**

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	16 September 2025
Name and title of authorised person:	Raelene Leonard, General Counsel & Company Secretary



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
16 September 2025
5 September 2025

Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Lyndal Jane York
Fisher & Paykel Healthcare Corporation Limited
Chief Financial Officer

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):

a) Options to acquire Ordinary Shares
b) Performance Share Rights
c) Ordinary Shares
Beneficial interest

For that relevant interest-

Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

a) 185,030 Options to acquire Ordinary Shares
b) 101,712 Performance Share Rights
c) 22,614 Ordinary Shares
a) 122,638 Options to acquire Ordinary Shares
b) 74,216 Performance Share Rights
c) 80,617 Ordinary Shares
a) Lyndal Jane York
b) Lyndal Jane York
c) Lyndal Jane York and Alexander Eric York
a) Lyndal Jane York
b) Lyndal Jane York
c) Lyndal Jane York and Alexander Eric York

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:


Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:


For that derivative,-

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:


Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:
---

Two
-----

